EU reveals proposals on pharma in TTIP talks
This article was originally published in Scrip
The European Commission has released a number of texts laying out the EU's proposals on specific issues, including pharmaceutical and medical device regulation, that are under discussion with the US government as part of the negotiations on the Transatlantic Trade and Investment Partnership (TTIP). The commission says this is the first time it has made such proposals public during bilateral trade talks, and that this "reflects its commitment to greater transparency in the negotiations".
You may also be interested in...
The UK government has awarded “urgent public health status” to a clinical trial program that will test one investigational product and four existing drugs in an effort to quickly find new treatments for patients hospitalized with serious COVID-19 infection.
Coronavirus Notebook: New Therapeutic Approaches, Fair Access To Dexamethasone, & Patent Help From The EPO
With COVID-19 cases about to top 12 million worldwide, efforts are continuing to identify the most promising drug candidates and to ensure that the rising star dexamethasone is made available to all.
Regulators have produced yet another strategy outlining the challenges and next steps for the European drug regulatory network as the network prepares for a future characterized by rapid developments in science and technology, medicines access issues, supply chain weaknesses and emerging health threats.